Guardant Health Inc.

158.50-0.7000-0.44%Vol 468.45K1Y Perf 129.37%
Apr 16th, 2021 16:00 DELAYED
BID150.00 ASK161.00
Open159.27 Previous Close159.20
Pre-Market- After-Market-
 - -  - -%
Target Price
181.71 
Analyst Rating
Strong Buy 1.00
Potential %
14.64 
Finscreener Ranking
★★★     50.66
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★+     50.28
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★     48.14
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap15.92B 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
79.79 
Earnings Date
6th May 2021

Today's Price Range

156.35159.66

52W Range

69.37181.07

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
0.85%
1 Month
8.67%
3 Months
-0.50%
6 Months
56.93%
1 Year
129.37%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
GH158.50-0.7000-0.44
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Financial StrengthValueIndustryS&P 500US Markets
27.70
28.30
0.40
0.66
-50.60
Leverage Ratio 1.50
ProfitabilityValueIndustryS&P 500US Markets
67.70
-64.60
-58.30
-112.20
-99.57
RevenueValueIndustryS&P 500US Markets
219.22M
2.18
68.93
-
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.44-0.94-113.64
Q03 2020-0.34-0.78-129.41
Q02 2020-0.40-0.57-42.50
Q01 2020-0.38-0.2923.68
Q04 2019-0.30-0.2710.00
Q03 2019-0.39-0.1464.10
Q02 2019-0.34-0.1361.76
Q01 2019-0.35-0.3014.29
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.82-78.26Negative
6/2021 QR-0.78-105.26Negative
12/2021 FY-3.38-154.14Negative
12/2022 FY-2.54-568.42Negative
Next Report Date6th May 2021
Estimated EPS Next Report-0.82
Estimates Count5
EPS Growth Next 5 Years %9.10
Volume Overview
Volume468.45K
Shares Outstanding100.43M
Trades Count9.51K
Dollar Volume451.78M
Avg. Volume1.02M
Avg. Weekly Volume615.49K
Avg. Monthly Volume799.98K
Avg. Quarterly Volume972.52K

Guardant Health Inc. (NASDAQ: GH) stock closed at 158.5 per share at the end of the most recent trading day (a -0.44% change compared to the prior day closing price) with a volume of 468.72K shares and market capitalization of 15.92B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 864 people. Guardant Health Inc. CEO is Helmy Eltoukhy.

The one-year performance of Guardant Health Inc. stock is 129.37%, while year-to-date (YTD) performance is 22.98%. GH stock has a five-year performance of %. Its 52-week range is between 69.37 and 181.07, which gives GH stock a 52-week price range ratio of 79.79%

Guardant Health Inc. currently has a PE ratio of -61.80, a price-to-book (PB) ratio of 12.34, a price-to-sale (PS) ratio of 71.01, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -15.29%, a ROC of -20.16% and a ROE of -23.41%. The company’s profit margin is -99.57%, its EBITDA margin is -58.30%, and its revenue ttm is $219.22 Million , which makes it $2.18 revenue per share.

Of the last four earnings reports from Guardant Health Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.82 for the next earnings report. Guardant Health Inc.’s next earnings report date is 06th May 2021.

The consensus rating of Wall Street analysts for Guardant Health Inc. is Strong Buy (1), with a target price of $181.71, which is +14.64% compared to the current price. The earnings rating for Guardant Health Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Guardant Health Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Guardant Health Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 20.08, ATR14 : 8.68, CCI20 : 61.98, Chaikin Money Flow : 0.11, MACD : -0.66, Money Flow Index : 70.35, ROC : 7.98, RSI : 42.17, STOCH (14,3) : 80.33, STOCH RSI : 0.96, UO : 55.60, Williams %R : -19.67), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Guardant Health Inc. in the last 12-months were: AmirAli Talasaz (Option Excercise at a value of $1 171 040), AmirAli Talasaz (Sold 2 151 656 shares of value $272 299 241 ), Derek A. Bertocci (Option Excercise at a value of $89 615), Derek A. Bertocci (Sold 97 089 shares of value $8 961 132 ), Dipchand Nishar (Sold 2 shares of value $200 ), Helmy Eltoukhy (Option Excercise at a value of $622 498), Helmy Eltoukhy (Sold 1 860 334 shares of value $262 721 024 ), Ian T. Clark (Option Excercise at a value of $155 170), Ian T. Clark (Sold 37 122 shares of value $3 612 841 ), Michael Wiley (Option Excercise at a value of $41 800), Michael Wiley (Sold 10 000 shares of value $787 042 ), Samir Kaul (Sold 45 000 shares of value $4 571 543 ), Stanley J. Meresman (Option Excercise at a value of $514 939), Stanley J. Meresman (Sold 86 690 shares of value $9 134 504 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (100.00 %)
7 (100.00 %)
8 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Guardant Health Inc.

Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company's pipeline includes Lunar-1, for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.

CEO: Helmy Eltoukhy

Telephone: +1 855 698-8887

Address: 505 Penobscot Drive, Redwood City 94063, CA, US

Number of employees: 864

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

55%45%

Bearish Bullish

52%48%

Bearish Bullish

47%53%

News

Stocktwits